- Home
- SNY vs APP Comparison
SNY vs APP Comparison
Compare SNY & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- APP
- Stock Information
- Founded
- SNY 1994
- APP 2012
- Country
- SNY France
- APP United States
- Employees
- SNY N/A
- APP N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- APP EDP Services
- Sector
- SNY Health Care
- APP Technology
- Exchange
- SNY Nasdaq
- APP Nasdaq
- Market Cap
- SNY 127.2B
- APP 125.4B
- IPO Year
- SNY N/A
- APP 2021
- Fundamental
- Price
- SNY $49.37
- APP $393.00
- Analyst Decision
- SNY Buy
- APP Buy
- Analyst Count
- SNY 2
- APP 20
- Target Price
- SNY $62.50
- APP $405.37
- AVG Volume (30 Days)
- SNY 2.4M
- APP 7.1M
- Earning Date
- SNY 07-24-2025
- APP 05-07-2025
- Dividend Yield
- SNY 4.48%
- APP N/A
- EPS Growth
- SNY 39.56
- APP 232.19
- EPS
- SNY 5.45
- APP 5.53
- Revenue
- SNY $48,817,552,946.00
- APP $5,135,154,000.00
- Revenue This Year
- SNY $3.39
- APP $24.92
- Revenue Next Year
- SNY $7.05
- APP $21.71
- P/E Ratio
- SNY $17.77
- APP $71.05
- Revenue Growth
- SNY N/A
- APP 41.63
- 52 Week Low
- SNY $45.80
- APP $60.67
- 52 Week High
- SNY $60.12
- APP $525.15
- Technical
- Relative Strength Index (RSI)
- SNY 38.24
- APP 67.30
- Support Level
- SNY $51.80
- APP $340.20
- Resistance Level
- SNY $52.41
- APP $402.90
- Average True Range (ATR)
- SNY 0.83
- APP 18.86
- MACD
- SNY -0.06
- APP 1.95
- Stochastic Oscillator
- SNY 16.44
- APP 84.21
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max, and gaming studios, which develop mobile games. AppLovin announced in February 2025 its plans to divest from the lower-margin gaming studios to focus exclusively on the ad tech platform. AppLovin's primary tool for future growth is Axon 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.